Cerdulatinib clinical trials
How each study uses cerdulatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Alexion Pharmaceuticals, Inc. (1) · Dermavant Sciences GmbH (1) · Portola Pharmaceuticals (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses cerdulatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnPhase 2/3Portola PharmaceuticalsNCT04021082Written as Cerdulatinib
- Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedPhase 1/2Alexion Pharmaceuticals, Inc.NCT01994382Written as Cerdulatinib
- Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With VitiligoCompletedPhase 2Dermavant Sciences GmbHNCT04103060Written as Cerdulatinib 0.37% gel
Codes
What other systems call cerdulatinib · ClinicalTrials.gg INT000179
- UNII (FDA) D1LXQ45S1OCERDULATINIBConfirmed FDA, Wikidata
- Wikidata Q27075860cerdulatinibConfirmed FDA, Wikidata
- NCI Thesaurus C113173CerdulatinibOne source FDA
- DrugBank DB15499One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D1LXQ45S1O | CERDULATINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27075860 | cerdulatinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C113173 | Cerdulatinib | One source FDA |
| DrugBank | DB15499 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.